Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Plant Allergenic Extract [EPC]
Strychnos Nux-vomica Seed is primarily classified as a Non-Standardized Plant Allergenic Extract. Due to its high alkaloid content, including strychnine, it is used under strict clinical supervision for specific diagnostic or therapeutic allergenic purposes.
Name
Strychnos Nux-vomica Seed
Raw Name
STRYCHNOS NUX-VOMICA SEED
Category
Non-Standardized Plant Allergenic Extract [EPC]
Drug Count
554
Variant Count
661
Last Verified
February 17, 2026
About Strychnos Nux-vomica Seed
Strychnos Nux-vomica Seed is primarily classified as a Non-Standardized Plant Allergenic Extract. Due to its high alkaloid content, including strychnine, it is used under strict clinical supervision for specific diagnostic or therapeutic allergenic purposes.
Detailed information about Strychnos Nux-vomica Seed
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Strychnos Nux-vomica Seed.
Strychnos Nux-vomica Seed is derived from the dried, ripe seeds of the Strychnos nux-vomica tree, native to Southeast Asia and India. In modern clinical pharmacology, it is classified as a Non-Standardized Plant Allergenic Extract [EPC]. Historically, the seeds were known for their potent alkaloid content, specifically strychnine and brucine. While it has been used in traditional medicine systems, its role in contemporary evidence-based medicine is largely restricted to allergenic testing and specific immunotherapy protocols where standardized extracts are required to identify or desensitize patients to plant-based allergens.
According to the FDA-approved allergenic product catalogs, Strychnos Nux-vomica Seed belongs to a class of drugs called allergenic extracts. These substances are used by specialists to diagnose or treat allergic reactions through controlled exposure. It is important to note that the raw seed is highly toxic and is not used for general systemic treatment in conventional medicine. The FDA has historically monitored the use of nux-vomica alkaloids due to their narrow therapeutic index and significant risk of toxicity.
The pharmacological activity of Strychnos Nux-vomica Seed is driven by its primary alkaloids, strychnine and brucine. At a molecular level, strychnine acts as a potent competitive antagonist at glycine receptors located in the spinal cord, brainstem, and higher centers of the central nervous system (CNS). By blocking these inhibitory receptors, the substance causes a state of generalized excitatory neurotransmission, which can lead to muscle spasms and convulsions if ingested in non-homeopathic or non-diagnostic quantities.
When used as an allergenic extract, the mechanism shifts toward the immune system. The extract contains proteins that, when introduced to the skin or mucous membranes, interact with IgE antibodies bound to mast cells. This interaction triggers the release of inflammatory mediators (like histamine), allowing clinicians to assess the patient's level of hypersensitivity to the plant material.
> Important: Only your healthcare provider can determine if Strychnos Nux-vomica Seed allergenic extract is appropriate for your diagnostic needs.
Dosage for Strychnos Nux-vomica Seed is highly specialized and depends entirely on the clinical application:
Strychnos Nux-vomica Seed extracts are generally not recommended for use in children unless specifically directed by a pediatric allergist. The risk of systemic toxicity and the sensitivity of the pediatric immune system require extreme caution.
Because the alkaloids are partially cleared by the kidneys, patients with severe renal impairment (CrCl < 30 mL/min) should be monitored closely for signs of systemic toxicity if any significant absorption occurs.
Patients with hepatic cirrhosis may have reduced clearance of nux-vomica alkaloids, increasing the risk of CNS excitation. Dosage should be approached with extreme caution.
Elderly patients may have increased sensitivity to the CNS effects of strychnine. Clinical monitoring for muscle stiffness or hyperreflexia is recommended during immunotherapy.
This substance should never be self-administered in its raw or extract form.
If an immunotherapy dose is missed, contact your allergist. Do not double the next dose, as this increases the risk of a systemic reaction.
Signs of overdose (strychnine poisoning) include extreme muscle stiffness, painful convulsions (triggered by light or sound), and difficulty breathing. This is a medical emergency. Immediate treatment involves airway management, benzodiazepines for seizures, and a quiet environment.
> Important: Follow your healthcare provider's dosing instructions precisely. Do not attempt to use raw nux-vomica seeds, as they are potentially lethal.
When used as an allergenic extract, the most common reactions are localized to the site of administration:
> Warning: Stop the procedure and call for emergency help if you experience any of the following:
Prolonged exposure to low levels of nux-vomica alkaloids can lead to increased reflex excitability and chronic sleep disturbances. There is no evidence of carcinogenic potential in humans at diagnostic doses.
Strychnos Nux-vomica Seed contains strychnine, a potent neurotoxin. Systemic absorption can lead to fatal convulsions and respiratory failure. Additionally, as an allergenic extract, this product can cause severe, life-threatening anaphylactic reactions. It must only be administered by healthcare professionals trained in emergency resuscitation.
Report any unusual symptoms to your healthcare provider immediately.
Strychnos Nux-vomica Seed is a substance with a high potential for toxicity. It must never be used as a dietary supplement in its raw form. All clinical use must be supervised by an allergist or immunologist. Patients with a history of seizures or neurological disorders are at a significantly higher risk.
No official FDA black box warning exists for the allergenic extract specifically, but clinical literature and the CDC emphasize the extreme lethality of the strychnine component found in the seed. Fatalities have been reported with as little as 30-100 mg of ingested strychnine.
Patients should avoid driving or operating heavy machinery for at least 1 hour after receiving an allergenic extract, as dizziness or systemic reactions can impair reaction times.
Alcohol should be avoided on the day of testing or treatment. Alcohol can mask the symptoms of a systemic reaction and may theoretically potentiate the CNS effects of nux-vomica alkaloids.
If a patient experiences a systemic reaction (Grade 2 or higher), the use of the extract must be discontinued or the dose significantly reduced. There is no withdrawal syndrome associated with discontinuing allergenic extracts.
> Important: Discuss all your medical conditions, especially neurological or heart issues, with your healthcare provider before starting Strychnos Nux-vomica Seed.
Strychnos Nux-vomica Seed does not typically interfere with standard blood chemistry or hematology tests. However, it will produce a positive result on specific skin tests for plant allergens.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those affecting the nervous system.
Patients allergic to other members of the Loganiaceae family may exhibit cross-reactivity to Strychnos Nux-vomica Seed extracts.
> Important: Your healthcare provider will evaluate your complete medical history, including neurological health, before prescribing this extract.
FDA Pregnancy Category X (Estimated). Strychnos Nux-vomica Seed is contraindicated in pregnancy. Strychnine readily crosses the placental barrier and is highly fetotoxic. It can cause uterine contractions and fetal neurological damage. It should never be used in women who are or may become pregnant.
Alkaloids from the seed, including strychnine, are excreted into breast milk. Due to the high sensitivity of the infant nervous system to glycine-receptor antagonists, breastfeeding is not recommended if the mother is being treated with non-homeopathic forms of this extract.
Safety and effectiveness in the pediatric population have not been established. Use in children is generally discouraged due to the risk of accidental systemic absorption and the severe nature of strychnine toxicity in smaller body masses.
Elderly patients should be monitored for increased sensitivity to CNS stimulants. Age-related declines in renal and hepatic function may necessitate lower doses in immunotherapy protocols to prevent accumulation.
In patients with a GFR < 60 mL/min, the clearance of strychnine metabolites is reduced. While diagnostic skin testing is generally safe, systemic immunotherapy requires cautious dose titration.
Child-Pugh Class B and C patients should avoid exposure to this extract. The liver is the primary site of alkaloid detoxification; impaired function significantly increases the half-life and toxicity of the substance.
> Important: Special populations require individualized medical assessment and often a consultation with a toxicologist or high-risk specialist.
Strychnos Nux-vomica Seed contains the indole alkaloids strychnine and brucine. Strychnine is a potent, selective antagonist of the inhibitory neurotransmitter glycine. It binds to the alpha-1 subunit of the glycine receptor in the spinal cord and brainstem. By preventing glycine from binding, it removes the normal inhibitory control over motor neurons, leading to unchecked reflex stimulation and tetanic convulsions.
| Parameter | Value |
|---|---|
| Bioavailability | >80% (Oral/Systemic) |
| Protein Binding | ~25% |
| Half-life | 10-12 hours |
| Tmax | 1-2 hours |
| Metabolism | Hepatic (CYP2B6) |
| Excretion | Renal (15% unchanged) |
Strychnos Nux-vomica Seed is classified as a Non-Standardized Plant Allergenic Extract [EPC]. It is related to other allergenic extracts used in diagnostic immunology, though it is unique due to its specific toxicological profile.
Medications containing this ingredient
Common questions about Strychnos Nux-vomica Seed
In modern clinical practice, Strychnos Nux-vomica Seed is primarily used as a non-standardized plant allergenic extract. It is employed by allergists to diagnose specific hypersensitivities through skin prick testing or, in rare cases, for allergen immunotherapy. Beyond its use in allergy medicine, it is also found in highly diluted homeopathic preparations, though these are not FDA-approved for treating specific diseases. The raw seed itself is not used for treatment due to its extreme toxicity. Always consult a healthcare professional before considering any product containing this ingredient.
The most common side effects occur when the extract is used for skin testing and include localized redness, itching, and a raised bump known as a 'wheal and flare' reaction. These symptoms are usually temporary and indicate a positive allergic response. If the substance is absorbed systemically, it can cause more serious effects like muscle stiffness, restlessness, or anxiety. In rare cases, severe allergic reactions like anaphylaxis can occur. Any unusual symptoms should be reported to a doctor immediately.
It is strongly advised to avoid alcohol when undergoing testing or treatment with Strychnos Nux-vomica Seed extracts. Alcohol can interfere with the body's immune response and may mask the early warning signs of a systemic allergic reaction or toxicity. Furthermore, alcohol has its own effects on the central nervous system that could potentially interact with the alkaloids found in the seed. To ensure the most accurate diagnostic results and maintain safety, refrain from alcohol for at least 24 hours around your appointment. Discuss your lifestyle habits with your allergist for specific guidance.
No, Strychnos Nux-vomica Seed is considered unsafe and is generally contraindicated during pregnancy. The primary alkaloid, strychnine, is a potent neurotoxin that can cross the placenta and potentially harm the developing fetus. It may also cause uterine contractions, which could increase the risk of miscarriage or preterm labor. There is no established safe dose for pregnant women in conventional medicine. If you are pregnant or planning to become pregnant, you must inform your healthcare provider before any exposure to this substance.
When used for allergenic skin testing, the reaction to Strychnos Nux-vomica Seed is rapid, typically appearing within 15 to 20 minutes. This quick onset allows clinicians to provide immediate diagnostic feedback during an office visit. If taken in a systemic form (which is highly discouraged outside of controlled clinical trials), the toxic effects of the alkaloids can begin within 30 minutes. The duration of the diagnostic skin reaction usually fades within a few hours. For immunotherapy, the 'work' of desensitization takes months of gradual exposure.
Because Strychnos Nux-vomica Seed is typically administered as a diagnostic test or a supervised immunotherapy injection, 'stopping' it usually just means not attending the next scheduled appointment. There are no known physical withdrawal symptoms associated with discontinuing this allergenic extract. However, stopping an immunotherapy program prematurely may result in the return of allergy symptoms. Always discuss your treatment plan with your allergist before making changes. They can help you weigh the benefits of continuing versus the risks of stopping.
If you miss a scheduled dose of Strychnos Nux-vomica Seed immunotherapy, you should contact your allergist's office as soon as possible. Missing a dose may require the doctor to adjust your next dose downward to ensure safety and prevent a systemic reaction. Do not attempt to 'make up' for a missed dose by taking extra, as this significantly increases the risk of toxicity. Your healthcare provider will determine the best schedule to get you back on track. Consistency is key to the success of allergen desensitization.
There is no clinical evidence to suggest that Strychnos Nux-vomica Seed causes weight gain. The amounts used in allergenic testing and immunotherapy are extremely small and do not affect metabolic processes related to fat storage or appetite. Unlike some other medications, such as certain steroids or antidepressants, this extract does not have a hormonal or metabolic profile linked to weight changes. If you experience unexpected weight gain, it is likely due to other factors and should be discussed with your primary care physician. Always report new or unusual symptoms to your medical team.
Strychnos Nux-vomica Seed can interact with several types of medications, particularly those that affect the central nervous system. It is especially dangerous to combine it with other stimulants or drugs that lower the seizure threshold. Additionally, medications like beta-blockers can make it harder to treat an allergic reaction if one occurs during testing. You must provide your doctor with a complete list of all prescriptions, over-the-counter drugs, and herbal supplements you are using. This allows them to safely manage your care and avoid potentially life-threatening interactions.
Strychnos Nux-vomica Seed is not a standard 'brand-name' drug but is available as a non-standardized allergenic extract from various specialized laboratories. Because it is a natural product used for specific diagnostic purposes, the concept of 'generic' vs. 'brand' works differently than with typical pills. Different manufacturers may produce extracts with varying potencies, so they are not always interchangeable. Your allergist will select a specific extract based on its purity and clinical history. Always ensure that any extract used is sourced from a reputable, regulated pharmaceutical supplier.